What's happening
Live detector signal
Generated 19:56 ET
GOSS — Gossamer Bio, Inc. Common Stock is up 7421.1%, at 10.71, on $4.3M traded. Score 78. Primary driver: $4.3M traded. Supply intelligence: mixed supply · 46.
Get alerts on $GOSS
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
453.6M
2026-06-11
Shares out
488.8M
latest detail
Market cap
$5.6B
at ref price
Short interest
18.2%
2026-08-31
Float rotation
0.00×
latest snapshot
20d dollar vol
$3.7M
baseline
Gap quality
mixed supply · 46
live supply-pressure model
Supply factor
positive gap demand
detector reason
Supply factor
large float supply
detector reason
Supply factor
elevated short interest
detector reason
Supply factor
microcap supply profile
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-09-11 14:55 ETSignalGossamer Bio, Inc. Common Stock is up 7421.1%, at 10.71, on $4.3M traded. Score 78. Primary driver: $4.3M traded. Supply intelligence: mixed supply · 46.
2026-09-11Split1-for-80 reverse split logged
2026-09-118-KItem 3.03 — Material modification to rights of security holders; Item 5.03 — Amendments to charter or bylaws +1 more SEC
2026-09-038-KItem 5.03 — Amendments to charter or bylaws; Item 9.01 — Financial statements and exhibits SEC
2026-08-268-KItem 5.03 — Amendments to charter or bylaws; Item 1.01 — Entry into a material definitive agreement +1 more SEC
2026-08-218-KItem 1.01 — Entry into a material definitive agreement; Item 3.02 — Unregistered sales of equity securities +1 more SEC
2026-08-138-KItem 2.02 — Results of operations and financial condition; Item 9.01 — Financial statements and exhibits SEC
2026-05-31 18:59 ETFDA / ClinicalGOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm News
2026-05-31 17:43 ETFDA / ClinicalGOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS News
2026-05-30 18:52 ETFDA / ClinicalGOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS News
2026-05-29 14:48 ETFDA / ClinicalGossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS News
Latest detector signalscore 78